Some good debate here, well most of it. When you consider a...

Some good debate here, well most of it.

When you consider a company like PEB Pacific Edge with CX Bladder, a brilliant and proven test for Bladder Cancer, well ahead in the development of Plaxib and yet they are struggling to get traction. That's my biggest concern. Their market is far bigger than Plaxib.

Anyway I guess we will have a good idea by the end of this year.

Cap raises, fair dinkum, it's a BS argument compared to the marketability of a product.